Cara Therapeutics Statistics

Total Valuation

Cara Therapeutics has a market cap or net worth of GBP 17.74 million. The enterprise value is 19.34 million.

Market Cap	17.74M
Enterprise Value	19.34M

Important Dates

The next estimated earnings date is Monday, March 3, 2025.

Earnings Date	Mar 3, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+1.28%
Shares Change (QoQ)	+0.22%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	3.90M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	33.63
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-0.27
EV / Sales	2.74
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-0.34

Financial Position

The company has a current ratio of 4.77, with a Debt / Equity ratio of 62.23.

Current Ratio	4.77
Quick Ratio	4.32
Debt / Equity	62.23
Debt / EBITDA	n/a
Debt / FCF	-0.57
Interest Coverage	-12.76

Financial Efficiency

Return on equity (ROE) is -221.25% and return on invested capital (ROIC) is -74.81%.

Return on Equity (ROE)	-221.25%
Return on Assets (ROA)	-61.79%
Return on Capital (ROIC)	-74.81%
Revenue Per Employee	117,830
Profits Per Employee	-1.30M
Employee Count	55
Asset Turnover	0.10
Inventory Turnover	57.11

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -35.03% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-35.03%
50-Day Moving Average	4.00
200-Day Moving Average	5.13
Relative Strength Index (RSI)	52.89
Average Volume (20 Days)	1,851

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	0.96

Income Statement

In the last 12 months, Cara Therapeutics had revenue of GBP 6.48 million and -71.27 million in losses. Loss per share was -15.66.

Revenue	6.48M
Gross Profit	-76.42M
Operating Income	-61.47M
Pretax Income	-71.27M
Net Income	-71.27M
EBITDA	-61.26M
EBIT	-61.47M
Loss Per Share	-15.66

Full Income Statement

Balance Sheet

The company has 31.36 million in cash and 32.83 million in debt, giving a net cash position of -1.47 million.

Cash & Cash Equivalents	31.36M
Total Debt	32.83M
Net Cash	-1.47M
Net Cash Per Share	n/a
Equity (Book Value)	527,493
Book Value Per Share	0.12
Working Capital	28.26M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -55.39 million and capital expenditures -2.31 million, giving a free cash flow of -57.70 million.

Operating Cash Flow	-55.39M
Capital Expenditures	-2.31M
Free Cash Flow	-57.70M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-948.50%
Pretax Margin	-1,099.76%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Cara Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.28%
Shareholder Yield	-1.28%
Earnings Yield	-401.71%
FCF Yield	-325.25%

Stock Splits

The last stock split was on December 31, 2024. It was a reverse split with a ratio of 0.0833333333.

Last Split Date	Dec 31, 2024
Split Type	Reverse
Split Ratio	0.0833333333

Scores

Cara Therapeutics has an Altman Z-Score of -24.18. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-24.18
Piotroski F-Score	n/a